Welcome to our dedicated page for Sol Gel Tech SEC filings (Ticker: SLGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sol-Gel Technologies Ltd.'s SEC filings document the disclosure record of a foreign private issuer developing and partnering dermatology drug products. Form 6-K reports include operating and financial results, unaudited condensed financial statements, clinical and regulatory updates for SGT-610, SGT-210 and EPSOLAY, and material-event disclosures incorporated by reference into the company's Form S-8 and Form F-3 registration statements.
The filings also cover shareholder meeting materials, auditor appointments, board elections, interim executive leadership approvals under Israeli corporate governance requirements, and capital-structure matters involving the company's ordinary shares. These documents frame Sol-Gel's public-company reporting around dermatology pipeline development, approved topical products, licensing arrangements, governance actions, and financing capacity.
Sol-Gel Technologies Ltd. director Arkin Itai Gidon filed an initial statement of beneficial ownership on Form 3. The filing lists him as a director of the company but does not report any buy, sell, or other share transactions in this submission.
Sol-Gel Technologies Ltd. executive Michael Glezin, the Chief Business Officer, has filed an initial ownership report showing his holdings in the company’s ordinary shares and stock options. This Form 3 does not reflect new trades but discloses his current equity position.
Glezin directly holds 1,500 Ordinary Shares and several stock option awards over ordinary shares. These options cover 2,500 shares at an exercise price of $49.80 expiring on November 2, 2032, 5,000 shares at $8.96 expiring on February 18, 2035, and 7,500 shares at $69.50 expiring on January 19, 2036. Footnotes state that each option vests 25% on a specified initial date, with the remaining 75% vesting in equal quarterly installments over three years, subject to his continued service.
Sol-Gel Technologies Ltd. executive Ofra Levy-Hacham, VP Clinical, Regulatory & Quality, filed an initial Form 3 reporting her beneficial ownership of several stock option grants over the company’s ordinary shares. These options are held directly, with exercise prices ranging from $8.96 to $100.00 per share and expiration dates between August 2026 and February 2035.
According to the filing, some of the options are already fully vested, while others began vesting 25% on specific dates in 2023, 2024, and 2026 and will continue to vest in equal quarterly installments over the following three years, subject to her continued service with the company.
Sol-Gel Technologies Ltd. executive Ofer Toledano, VP Research & Development, filed an initial insider ownership report. He directly holds 1,461 Ordinary Shares and a series of stock options over Ordinary Shares with exercise prices ranging from 8.9600 to 100.0000, expiring between 2026 and 2035. Several options are already fully vested, while others vest in quarterly installments over three years, contingent on continued service.
Sol-Gel Technologies Ltd. Chairman and CEO Moshe Arkin filed an initial ownership report showing his stake in the company. He reports indirect ownership of warrants giving the right to buy 200,000 ordinary shares at an exercise price of $58.50 per share, expiring on January 27, 2028, through M. Arkin Dermatology Ltd. He also reports 143,257 ordinary shares held directly and 1,606,856 ordinary shares held indirectly through M. Arkin Dermatology Ltd. A footnote states he disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
SLGL filed a Form 144 reporting proposed sales of Ordinary shares under an Employee Stock Option Plan, to be settled for cash upon exercise.
The excerpt lists two dispositions by Yosef Itzik during the past three months: 1,168 Ordinary shares on 01/07/2026 for $70,250.51 and 2,726 Ordinary shares on 02/23/2026 for $240,192.00. The filing references Nasdaq and Ordinary share class.
Form 144 filing reporting proposed sale of ordinary shares through Oppenheimer & Co. The filing lists 1,556 ordinary shares tied to an employee stock option plan with a broker of record of Oppenheimer & Co. Inc. and a broker date of 02/25/2026. The excerpt includes per-holder examples, including Yosef Itzik: 1,168 shares on 01/07/2026 and 1,170 shares on 02/23/2026, with associated dollar figures shown in the rows. Cash upon exercise is shown as the method for the plan.
Itzik Yosef filed a Form 144 to sell 1,170 ordinary shares of SLGL. The filing lists the proposed sale date as 02/23/2026 and indicates the transaction method as Cash Upon Exercise. The filing also records a prior sale of 1,168 ordinary shares on 01/07/2026.
Opaleye Management Inc., a more than ten percent owner of Sol-Gel Technologies Ltd., reported an indirect open-market purchase of 291 ordinary shares of Sol-Gel on February 13, 2026 at a price of $63.00 per share, through Opaleye, L.P.
After this transaction, Opaleye, L.P. held 450,335 ordinary shares, and a separately managed account overseen by Opaleye held 10,000 ordinary shares. Opaleye Management Inc. disclaims beneficial ownership of these shares except to the extent of its pecuniary interest.
Sol-Gel Technologies Ltd. reported an amended insider filing for Opaleye Management Inc., a more than 10% holder. Through Opaleye, L.P., a related fund, there was an open-market purchase of 100 ordinary shares at a price of 58.0000 per share on 2026-02-02.
After this trade, Opaleye, L.P. held 450,044 shares, and a separately managed account associated with Opaleye held 10,000 shares, both reported as indirect ownership. The amendment states it corrects the previously reported beneficially owned share count due to a clerical error, and Opaleye Management Inc. disclaims beneficial ownership except to the extent of its pecuniary interest.